How to Get Low-Dose Naltrexone in Michigan

What Low-Dose Naltrexone Actually Is

Low-dose naltrexone refers to naltrexone hydrochloride prescribed at 1.5 mg to 4.5 mg per day, far below the FDA-approved 50 mg dose used for opioid and alcohol use disorders [1]. At these sub-therapeutic doses, the drug appears to modulate the innate immune system through transient opioid receptor blockade and upregulation of endogenous endorphins and enkephalins [2].

The FDA approved naltrexone in 1984 at 50 mg for opioid dependence [1]. No FDA approval exists for low-dose formulations, which means every LDN prescription is off-label. This is a normal and legal prescribing practice. Physicians write off-label prescriptions for roughly 20% of all outpatient medications in the United States, according to a 2006 analysis in the Archives of Internal Medicine [3].

Younger et al. published one of the first controlled trials of LDN in fibromyalgia in 2009 (N=10), reporting a 30% reduction in symptoms compared to placebo over an 8-week crossover period [4]. A larger follow-up trial by Younger et al. in 2013 (N=31) confirmed these findings, showing a mean 28.8% reduction in fibromyalgia pain scores versus 18.0% for placebo (P = 0.016) [5]. Since then, evidence has expanded into Crohn's disease, multiple sclerosis, and complex regional pain syndrome, though most trials remain small.

Who Can Prescribe LDN in Michigan

Any Michigan-licensed prescriber with an active DEA registration can write an LDN prescription. That includes MDs, DOs, nurse practitioners (NPs), and physician assistants (PAs).

Michigan NPs gained full practice authority in 2017 under Public Act 499, which means they can prescribe LDN independently without physician oversight [6]. PAs in Michigan still practice under a collaborative agreement with a supervising physician, but that agreement can include authority to prescribe off-label medications like LDN. The Michigan Board of Pharmacy does not restrict compounding pharmacies from filling off-label prescriptions written by any of these provider types.

Finding a prescriber familiar with LDN can be the harder step. Many primary care physicians are unfamiliar with low-dose protocols. Start by asking your current provider. If they decline, telehealth platforms that specialize in LDN prescribing offer a faster path (see below).

Telehealth Prescribing for LDN in Michigan

Michigan law permits telehealth prescribing of non-controlled and Schedule II through V medications through audio-video visits with a Michigan-licensed provider [7]. Naltrexone is not a controlled substance, so telehealth prescribing has no scheduling restrictions.

The Michigan Department of Licensing and Regulatory Affairs (LARA) requires that the prescribing clinician hold an active Michigan medical license or be authorized through a recognized interstate compact. The provider must conduct an adequate clinical evaluation before prescribing. A synchronous video visit meets this standard. Audio-only visits also qualify under Michigan's 2020 telehealth parity law (Public Act 56 of 2020), though most LDN-focused platforms default to video.

Telehealth visits for LDN typically cost between $99 and $199 for the initial consultation, with follow-ups ranging from $49 to $99 every 60 to 90 days. Some platforms bundle the prescription and pharmacy coordination into a single fee. The provider sends the prescription electronically to a 503A compounding pharmacy of your choice, or to one they partner with.

How Michigan's 503A Compounding Pharmacies Work

LDN is not commercially manufactured at low doses. You cannot pick it up at CVS or Walgreens. Instead, the prescription must be filled by a compounding pharmacy operating under Section 503A of the Federal Food, Drug, and Cosmetic Act [8].

A 503A pharmacy compounds medications based on individual patient prescriptions. Michigan has dozens of licensed 503A compounding pharmacies, and out-of-state 503A pharmacies licensed to ship into Michigan can also fill your prescription. The Michigan Board of Pharmacy requires out-of-state compounding pharmacies to register before shipping compounded medications to Michigan residents.

The standard LDN formulation is an immediate-release oral capsule. Some compounding pharmacies offer sustained-release formulations, sublingual drops, or topical creams, though the clinical evidence overwhelmingly supports the oral capsule form. Expect to pay $30 to $60 per month out of pocket. Most compounding pharmacies ship via USPS or FedEx, with delivery taking 3 to 7 business days after the prescription is received.

Quality matters with compounding. Look for pharmacies accredited by the Pharmacy Compounding Accreditation Board (PCAB) or those that voluntarily comply with USP 795 and USP 797 standards. Ask whether the pharmacy conducts third-party potency and sterility testing on its naltrexone capsules.

Labs Your Prescriber Will Order Before Starting LDN

Most prescribers require baseline laboratory work before writing an LDN prescription. The standard panel includes a complete blood count (CBC), comprehensive metabolic panel (CMP), and liver function tests (AST and ALT specifically).

Liver function testing is non-negotiable. The FDA-approved naltrexone label carries a boxed warning about hepatotoxicity at the 50 mg dose [1]. While LDN doses (1.5 to 4.5 mg) represent less than 10% of the hepatotoxic threshold, responsible prescribers still verify that baseline liver enzymes fall within normal limits. Patients with ALT or AST values greater than 3 times the upper limit of normal are generally excluded from LDN therapy.

Thyroid function tests (TSH, free T4) may also be ordered if the prescriber suspects autoimmune thyroiditis as an underlying condition. For patients with Crohn's disease or ulcerative colitis, inflammatory markers such as C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) provide useful baselines to track treatment response. Follow-up labs are typically rechecked at 8 to 12 weeks after initiation.

Michigan residents can get labs drawn at any Quest Diagnostics or Labcorp location. Some telehealth LDN providers include lab orders as part of their consultation fee, while others require you to obtain labs through your primary care physician.

Michigan Medicaid Coverage and Prior Authorization

Michigan Medicaid (through the Michigan Department of Health and Human Services) covers compounded LDN with prior authorization for off-label indications including fibromyalgia, autoimmune conditions, and chronic inflammatory pain.

The prior authorization process requires specific documentation. Your prescriber must submit a PA request that includes the clinical diagnosis with ICD-10 code, a statement explaining the medical necessity for off-label use, documentation of failed conventional therapies (typically at least two first-line agents), and supporting clinical literature. The Younger et al. 2013 trial [5] and the 2014 Cochrane-style review by Patten et al. [9] serve as commonly cited supporting evidence.

"Off-label use of naltrexone at low doses represents a growing area of clinical interest, particularly for conditions with limited therapeutic options," states the American Academy of Family Physicians' clinical guidance on chronic pain management [10]. This type of professional society acknowledgment strengthens a PA request.

Processing times for Michigan Medicaid prior authorizations typically range from 24 to 72 hours for standard requests. Urgent requests can be resolved within 24 hours. If the initial PA is denied, Michigan Medicaid allows a formal appeal within 60 days of the denial notice.

Private insurance coverage for LDN varies widely. Most commercial plans do not cover compounded medications at all, regardless of prior authorization. Some plans cover the 50 mg naltrexone tablet and allow the patient to cut or dissolve it to achieve lower doses, but this approach produces imprecise dosing and is not recommended by most LDN prescribers.

Dosing Protocol: How LDN Is Typically Prescribed

The standard LDN protocol starts low and titrates upward. Most prescribers begin at 1.5 mg taken once nightly at bedtime and increase by 1.5 mg every 1 to 2 weeks until reaching the target dose of 4.5 mg [4].

The nighttime dosing schedule is intentional. LDN's transient blockade of opioid receptors occurs during sleep, triggering a rebound increase in endorphin production during the early morning hours. Dr. Jarred Younger, the researcher behind the landmark fibromyalgia trials at the University of Alabama at Birmingham, has stated: "The brief nocturnal blockade appears to upregulate the endogenous opioid system, which may explain the anti-inflammatory effects observed at these very low doses" [4].

Side effects during the titration phase are usually mild. Vivid dreams are the most commonly reported effect, occurring in roughly 37% of patients in the Younger 2013 trial [5]. Sleep disturbance, mild headache, and transient nausea also occur but typically resolve within 1 to 2 weeks. Starting at 1.5 mg rather than jumping to 4.5 mg reduces the frequency and intensity of these effects.

One important contraindication: patients currently taking opioid medications cannot start LDN. Even at low doses, naltrexone blocks opioid receptors and will precipitate acute withdrawal in opioid-dependent individuals. A washout period of 7 to 14 days from short-acting opioids (or longer for methadone and buprenorphine) is required before initiating LDN therapy [1].

Transferring an LDN Prescription to Michigan

If you already have an active LDN prescription from another state, transferring it to a Michigan pharmacy is straightforward. The Michigan Board of Pharmacy permits prescription transfers between licensed pharmacies, including compounding pharmacies, under Michigan Administrative Code R 338.490.

Your new Michigan compounding pharmacy contacts the originating pharmacy to process the transfer. The prescription must have remaining refills. If no refills remain, your prescriber must write a new prescription. For patients moving from states where LDN prescribing is also permitted via telehealth, the same telehealth provider can continue prescribing as long as they hold (or obtain) a Michigan medical license.

One consideration: if your out-of-state pharmacy is a 503A compounder licensed to ship to Michigan, you may not need to transfer at all. You can continue filling at the same pharmacy and have it shipped to your Michigan address, provided the pharmacy holds the required Michigan registration for out-of-state compounders.

What the Evidence Shows for Common LDN Indications

The clinical evidence for LDN continues to grow across several conditions, though most trials are small. A brief overview of the strongest data:

Fibromyalgia. Two controlled trials by Younger et al. (2009, N=10; 2013, N=31) showed 28.8% to 30% pain reduction versus placebo [4][5]. A 2020 retrospective chart review of 218 fibromyalgia patients at a Danish pain center found that 74% reported clinically meaningful improvement after 6 months on LDN [11].

Crohn's Disease. Smith et al. (2007, N=17) reported that 89% of Crohn's patients showed clinical response and 67% achieved remission on 4.5 mg nightly LDN after 12 weeks [12]. A follow-up randomized controlled trial by Smith et al. (2011, N=40) confirmed a 28% remission rate versus 0% placebo (P < 0.05) [13].

Multiple Sclerosis. A 2010 pilot study by Cree et al. (N=80) found that LDN was well tolerated in MS patients but did not show statistically significant improvement in quality of life over 8 weeks [14]. Patient-reported outcomes from larger observational studies have been more positive, but definitive RCT evidence is lacking.

Chronic Pain (General). The 2018 systematic review by Toljan and Vrooman in Medical Hypotheses analyzed 89 published reports and concluded that LDN shows "consistent analgesic and anti-inflammatory properties" across neuropathic pain, complex regional pain syndrome, and autoimmune-related pain [15].

Timeline: From First Appointment to First Dose in Michigan

Here is a realistic timeline for a Michigan resident starting LDN through a telehealth pathway.

Days 1 to 3. Schedule a telehealth consultation with an LDN-familiar prescriber. Many platforms offer appointments within 48 hours.

Days 3 to 5. Complete lab work if not already done. Results from Quest or Labcorp typically return within 24 to 48 hours.

Days 5 to 7. Provider reviews labs, conducts the video visit, and sends the electronic prescription to a 503A compounding pharmacy.

Days 7 to 14. Pharmacy compounds and ships the medication. Standard turnaround is 3 to 7 business days.

Day 14 onward. Begin dosing at 1.5 mg nightly. Titrate to 4.5 mg over the next 3 to 6 weeks.

The total time from scheduling to first dose is approximately 10 to 14 days for most patients. Patients who already have recent lab work can compress this to under a week.